Flaws in a Tumor’s Genetic Mending Kit Drive Treatment Response to Immunotherapy – Newswise (press release)
|
Flaws in a Tumor’s Genetic Mending Kit Drive Treatment Response to Immunotherapy
Newswise (press release) “Our study results may lead to a new standard-of-care that includes mismatch repair deficiency testing to help identify a wider group of patients who have failed other therapies but may benefit from immunotherapy drugs.” says Dung Le, M.D., oncologist … |
Muscular Dystrophy News |
Gene Therapy Shows Long–Lasting Effects in Animal Model of Myotubular Myopathy
Muscular Dystrophy News A gene therapy treatment may restore the genetic mutations of myotubular myopathy, a type of muscular dystrophy that affects the skeletal muscles. In a previous study, a team of researchers at the University of Washington School of Medicine in Seattle … |
TheStreet.com |
Inovio’s HPV Immunotherapy Moves to Phase III, Stock Rises
Zacks.com Inovio Pharmaceuticals, Inc’s (INO – Free Report) shares rose over 10% after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human … Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-CancerClinical Leader FDA lifts clinical hold on HPV vaccine trialThe Pharma Letter (registration) |
TheStreet.com |
Inovio’s HPV Immunotherapy Moves to Phase III, Stock Rises
Zacks.com Inovio Pharmaceuticals, Inc’s (INO – Free Report) shares rose over 10% after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human … Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-CancerClinical Leader FDA lifts clinical hold on HPV vaccine trialThe Pharma Letter (registration) |
Spectrum |
CRISPR hack unearths gems buried in ‘dark genome’
Spectrum Tweaks to the CRISPR gene-editing system allow researchers to identify stretches of DNA that regulate gene expression. Researchers could use the method to find sequences that control genes tied to autism. The CRISPR system uses RNA guides to direct … |
pharmaphorum |
Novartis considers “pay-for-performance” for CAR–T
pharmaphorum Novartis is considering a “pay-for-performance” pricing scheme if its CAR–T therapy gets approved, following trial results published earlier this week. Results of the phase 2 JULIET study of 51 patients in relapsed or refractory diffuse large B-cell … CAR–T pricing decision looms large for NovartisThe Pharma Letter (registration) |